Every material Form 8-K Amylyx Pharmaceuticals, Inc. has filed with the SEC since August 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Amylyx reported a third-quarter 2026 net loss of $45.5 million, or $0.38 per share, up from $34.4 million, or $0.37 per share, a year earlier, as research and development and selling, general and administrative costs rose. The company also reported positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia and said a New Drug Application remains on track for submission by year-end 2026, while cash rose to $768.1 million after an equity offering with net proceeds of about $544.6 million.
Net loss for the quarter ended September 30, 2026 was $45.5 million, or $0.38 per share, versus $34.4 million, or $0.37 per share, in the same period of 2025.
R&D expenses were $28.4 million versus $19.9 million, and SG&A expenses were $21.3 million versus $16.2 million.
LUCIDITY showed a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo, with a p-value of 0.000003.
Cash, cash equivalents and marketable securities were $768.1 million at September 30, 2026, up from $250.8 million at June 30, 2026.
Amylyx entered a manufacturing and supply agreement with Bachem on September 8, 2026, and a term sheet with Polypeptide Group on September 1, 2026, to supply its long-term commercial needs for avexitide drug substance, if approved. The company will pay Polypeptide a $30 million upfront fee for capacity reservation, and both suppliers are non-exclusive.
Bachem Manufacturing Agreement signed September 8, 2026, with an initial five-year term that renews automatically for three-year periods
Polypeptide Term Sheet signed September 1, 2026, with a $30 million upfront fee for capacity reservation; a definitive agreement is still to be negotiated
Both agreements require minimum annual purchases beginning in 2028, with supply prices adjusted annually
Full agreements will be filed as exhibits to the Form 10-Q for the quarter ending September 30, 2026
On August 19, 2026, Amylyx entered an underwriting agreement to sell 14,090,000 new shares of common stock at $35.50 per share, with a 30-day option for underwriters to buy up to 2,113,500 more. Expected net proceeds are about $471.7 million, or about $542.5 million if the option is exercised in full, and the company plans to use them to fund a potential U.S. launch of avexitide if approved, add manufacturing capacity, and for research, working capital and general corporate purposes. The offering is expected to close on August 21, 2026, and the new shares add to the company's outstanding share count.
14,090,000 firm shares offered at $35.50 per share, all sold by the company
Underwriters have a 30-day option to buy up to 2,113,500 additional shares
Expected net proceeds of about $471.7 million, or about $542.5 million if the option is fully exercised
Offering expected to close on August 21, 2026, subject to customary closing conditions
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Amylyx Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →